1

Hereditary Angioedema (HAE) Treatment Market (By Drug Class: C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others; By Treatment Type: Prophylaxis, On-demand; By Route Of Administration: Intravenous, Subcutaneous, Oral) - Global Industry Analysis, Market Size, Opportunities And Forecast 2020 - 2027

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 190

CHAPTER 1. Industry Overview of Hereditary Angioedema (HAE) Treatment
1.1. Definition and Scope
1.1.1. Definition of Hereditary Angioedema (HAE) Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Hereditary Angioedema (HAE) Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Hereditary Angioedema (HAE) Treatment Market By Drug Class
1.2.3. Hereditary Angioedema (HAE) Treatment Market By Treatment Type
1.2.4. Hereditary Angioedema (HAE) Treatment Market By Route of Administration
1.2.5. Hereditary Angioedema (HAE) Treatment Market by Regions

CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources

CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Hereditary Angioedema (HAE) Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Hereditary Angioedema (HAE) Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players

CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Hereditary Angioedema (HAE) Treatment Major Manufacturers in 2019

CHAPTER 5. Hereditary Angioedema (HAE) Treatment Market By Drug Class
5.1. Introduction
5.2. Hereditary Angioedema (HAE) Treatment Revenue By Drug Class
5.2.1. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) and Forecast, By Drug Class, 2016-2027
5.2.2. C1-esterase inhibitor
5.2.2.1. C1-esterase inhibitor Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Bradykinin B2 receptor antagonist
5.2.3.1. Bradykinin B2 receptor antagonist Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.4. Kallikrein inhibitor
5.2.4.1. Kallikrein inhibitor Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.5. Others
5.2.5.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027

CHAPTER 6. Hereditary Angioedema (HAE) Treatment Market Revenue By Treatment Type
6.1. Introduction
6.2. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) By Treatment Type
6.2.1. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
6.2.2. Prophylaxis
6.2.2.1. Prophylaxis Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. On-demand
6.2.3.1. On-demand Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027

CHAPTER 7. Hereditary Angioedema (HAE) Treatment Market By Route of Administration
7.1. Introduction
7.2. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) By Route of Administration
7.2.1. Hereditary Angioedema (HAE) Treatment Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
7.2.2. Intravenous
7.2.2.1. Intravenous Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.3. Subcutaneous
7.2.3.1. Subcutaneous Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.4. Oral
7.2.4.1. Oral Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027

CHAPTER 8. North America Hereditary Angioedema (HAE) Treatment Market By Country
8.1. North America Hereditary Angioedema (HAE) Treatment Overview
8.2. U.S.
8.2.1. U.S. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.2.2. U.S. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
8.2.3. U.S. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
8.3. Canada
8.3.1. Canada Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.3.2. Canada Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
8.3.3. Canada Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
8.4. North America PEST Analysis

CHAPTER 9. Europe Hereditary Angioedema (HAE) Treatment Market By Country
9.1. Europe Hereditary Angioedema (HAE) Treatment Market Overview
9.2. U.K.
9.2.1. U.K. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.2.2. U.K. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.2.3. U.K. Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.3. Germany
9.3.1. Germany Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.3.2. Germany Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.3.3. Germany Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.4. France
9.4.1. France Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.4.2. France Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.4.3. France Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.5. Spain
9.5.1. Spain Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.5.2. Spain Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.5.3. Spain Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.6. Rest of Europe
9.6.1. Rest of Europe Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.6.2. Rest of Europe Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016-2027
9.6.3. Rest of Europe Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016-2027
9.7. Europe PEST Analysis

CHAPTER 10. Asia Pacific Hereditary Angioedema (HAE) Treatment Market By Country
10.1. Asia Pacific Hereditary Angioedema (HAE) Treatment Market Overview
10.2. China
10.2.1. China Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.2.2. China Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
10.2.3. China Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
10.3. Japan
10.3.1. Japan Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.3.2. Japan Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
10.3.3. Japan Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
10.4. India
10.4.1. India Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.4.2. India Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
10.4.3. India Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
10.5. Australia
10.5.1. Australia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.5.2. Australia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
10.5.3. Australia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
10.6. South Korea
10.6.1. South Korea Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.6.2. South Korea Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
10.6.3. South Korea Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.7.2. Rest of Asia-Pacific Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
10.7.3. Rest of Asia-Pacific Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
10.8. Asia Pacific PEST Analysis

CHAPTER 11. Latin America Hereditary Angioedema (HAE) Treatment Market By Country
11.1. Latin America Hereditary Angioedema (HAE) Treatment Market Overview
11.2. Brazil
11.2.1. Brazil Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
11.2.2. Brazil Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
11.2.3. Brazil Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
11.3. Mexico
11.3.1. Mexico Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
11.3.2. Mexico Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
11.3.3. Mexico Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
11.4. Rest of Latin America
11.4.1. Rest of Latin America Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
11.4.2. Rest of Latin America Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 – 2027
11.4.3. Rest of Latin America Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027

CHAPTER 12. Middle East & Africa Hereditary Angioedema (HAE) Treatment Market By Country
12.1. Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Overview
12.2. Saudi Arabia
12.2.1. Saudi Arabia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
12.2.2. Saudi Arabia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
12.2.3. Saudi Arabia Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
12.3. UAE
12.3.1. UAE Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
12.3.2. UAE Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
12.3.3. UAE Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
12.4.2. Rest of Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Treatment Type, 2016 - 2027
12.4.3. Rest of Middle East & Africa Hereditary Angioedema (HAE) Treatment Market Revenue (US$ Mn) and Forecast By Route of Administration, 2016 - 2027

CHAPTER 13. Player Analysis Of Hereditary Angioedema (HAE) Treatment
13.1. Hereditary Angioedema (HAE) Treatment Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Hereditary Angioedema (HAE) Treatment Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements

CHAPTER 14. COMPANY PROFILE
14.1. BIOCRYST PHARMACEUTICALS, INC.
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Mn), 2019
14.1.3.2. BIOCRYST PHARMACEUTICALS, INC. 2019 Hereditary Angioedema (HAE) Treatment Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Recent Developments & Business Strategy
14.1.6. Manufacturing Plant Footprint Analysis
14.2. Ionis Pharmaceuticals
14.3. Pharming Group NV
14.4. CSL Limited
14.5. Takeda Pharmaceutical Company Limited.
14.6. Attune Pharmaceuticals.
14.7. Adverum Biotechnologies, Inc.
14.8. KalVista Pharmaceuticals
14.9. Others

Cart Summary